With residual cancer, patients can become eligible for abemaciclib (a CDK4/6 inhibitor) if they have high-risk, ER+ disease, or for the antibody–drug conjugate trastuzumab-emtansine (TDM1) if the tumor is HER2+. This evidence concerns the gene ESR1 and neoplasm.